Last 12 months
Inside the activity.
5 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 2 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 3 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2018 Filed Jun 11, 2018 11:10 UTC |
Grossman Jerrold BDirector
|
PurchaseCommon Stock | 31,381 | $4.78 | $150,001.18 |
DisclosureSEC source: 0001193805-18-000821 · e618087_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,381 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by the Jerrold Grossman 2012 Nevada SLAT, of which Dr. Grossman serves as investment trustee. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:10 UTC |
Grossman Jerrold BDirector
|
PurchaseCommon Stock | 20,921 | $4.78 | $100,002.38 |
DisclosureSEC source: 0001193805-18-000821 · e618087_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,007 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:09 UTC |
Guiheen Lawrence P.Director
|
PurchaseCommon Stock | 20,000 | $4.78 | $95,600.00 |
DisclosureSEC source: 0001193805-18-000819 · e618085_4-guiheen.xml · nonDerivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:09 UTC |
Grossman Adam SDirector · President and CEO
|
PurchaseCommon Stock | 52,301 | $4.78 | $249,998.78 |
DisclosureSEC source: 0001193805-18-000820 · e618086_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 796,301 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:09 UTC |
Grossman Adam SDirector · President and CEO
|
PurchaseCommon Stock | 20,921 | $4.78 | $100,002.38 |
DisclosureSEC source: 0001193805-18-000820 · e618086_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,527 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| May 14, 2018 Filed May 16, 2018 21:00 UTC |
Biotest AG10% owner
Biotest Pharmaceuticals Corp10% owner
|
SaleNon-Voting Common Stock | 8,591,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-18-000697 · e618019_4-biotest.xml · nonDerivative · entry 1 Biotest AG · CIK 0001709152 · 10% owner Biotest Pharmaceuticals Corp · CIK 0001708960 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 0 F1 · shares: On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among, among other parties, the issuer, Biotest Pharmaceuticals Corporation ("BPC") and Biotest AG, BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock. F2 · ownership.nature: The shares were owned directly by BPC, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Read SEC document |
| May 14, 2018 Filed Aug 9, 2018 20:33 UTC |
Biotest Divestiture Trust10% owner
|
SaleNon-Voting Common Stock | 8,591,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000892 · edgar.xml · nonDerivative · entry 1 Biotest Divestiture Trust · CIK 0001748876 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 0 F1 · shares: On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among the issuer, Biotest AG, Biotest Pharmaceuticals Corporation ("BPC"), Biotest US Corporation ("Biotest US"), and The Biotest Devestiture Trust (the "Trust"), BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock. F2 · ownership.nature: Represents securities owned by BPC. BPC is a wholly-owned subsidiary of Biotest US, which is wholly-owned by the Trust. Eric Rosenbach, the trustee of the Trust, is the sole director of each of BPC and Biotest US and has voting and investment discretion with respect to the securities of the issuer held by BPC. Mr. Rosenbach has no pecuniary interest in such securities. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 21:01 UTC |
LENZ BRIANVP, CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001193805-18-000189 · e617683_4-lenz.xml · derivative · entry 1 LENZ BRIAN · CIK 0001283260 · VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:01 UTC |
Mond JamesEVP, CSO and CMO
|
GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001193805-18-000190 · e617684_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 02:00 UTC |
Grossman Adam SDirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001193805-18-000188 · e617682_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 13:49 UTC |
LENZ BRIANVP, CFO
|
PurchaseCommon Stock | 6,500 | $2.15 | $13,975.00 |
DisclosureSEC source: 0001193805-17-003453 · e617470_4-lenz.xml · nonDerivative · entry 1 LENZ BRIAN · CIK 0001283260 · VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 13:51 UTC |
RICHMAN ERIC IDirector
|
PurchaseCommon Stock | 25,000 | $2.15 | $53,750.00 |
DisclosureSEC source: 0001193805-17-003455 · e617474_4-richman.xml · nonDerivative · entry 1 RICHMAN ERIC I · CIK 0001313876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,300 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:54 UTC |
Biotest AGDirector · 10% owner
Biotest Pharmaceuticals CorpDirector · 10% owner
|
PurchaseCommon Stock | 5,813,954 | $2.15 | $12,500,001.10 |
DisclosureSEC source: 0001193805-17-003457 · e617475_4-biotest.xml · nonDerivative · entry 1 Biotest AG · CIK 0001709152 · Director · 10% owner Biotest Pharmaceuticals Corp · CIK 0001708960 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 10,109,534 F1 · shares: Represents a purchase from the underwriters in the issuer's public offering. F2 · ownership.nature: The shares are owned directly by Biotest Pharmaceuticals Corporation, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Biotest AG is a director and a ten percent owner of the issuer. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:45 UTC |
Mond JamesEVP, CSO and CMO
|
PurchaseCommon Stock | 10,000 | $2.15 | $21,500.00 |
DisclosureSEC source: 0001193805-17-003449 · e617468_4-mond.xml · nonDerivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,389 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:46 UTC |
Grossman Adam SDirector · President and CEO
|
PurchaseCommon Stock | 485,000 | $2.15 | $1,042,750.00 |
DisclosureSEC source: 0001193805-17-003451 · e617469_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 744,000 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. Read SEC document |
| November 09, 2017 Filed Nov 17, 2017 02:32 UTC Amendment |
Biotest AGDirector · 10% owner
Biotest Pharmaceuticals CorpDirector · 10% owner
|
PurchaseCommon Stock | 5,813,954 | $2.15 | $12,500,001.10 |
DisclosureSEC source: 0001193805-17-003506 · e617500_4a-biotest.xml · nonDerivative · entry 1 Biotest AG · CIK 0001709152 · Director · 10% owner Biotest Pharmaceuticals Corp · CIK 0001708960 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 10,109,534 F1 · shares: Represents a purchase from the underwriters in the issuer's public offering. F2 · ownership.nature: The shares are owned directly by Biotest Pharmaceuticals Corporation, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Biotest AG is a director and a ten percent owner of the issuer. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 17:12 UTC |
RICHMAN ERIC IDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001193805-17-001298 · e616384_4-richman.xml · derivative · entry 2 RICHMAN ERIC I · CIK 0001313876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,800 shares Expires 2017-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vested in equal monthly installments over the four (4) year period following July 16, 2007. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 17:12 UTC |
RICHMAN ERIC IDirector
|
Exercise / conversionCommon Stock | 2,800 | $2.68 | $7,504.00 |
DisclosureSEC source: 0001193805-17-001298 · e616384_4-richman.xml · nonDerivative · entry 1 RICHMAN ERIC I · CIK 0001313876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:14 UTC |
Grossman Adam SDirector · President and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 42,021 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · derivative · entry 5 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,021 shares Expires 2017-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on July 16, 2007 (the "First Anniversary Date"), and the remaining seventy-five percent (75%) of the shares subject to the option vested in equal monthly installments over the three (3) year period following the First Anniversary Date. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:14 UTC |
Grossman Adam SDirector · President and CEO
|
Tax withholdingCommon Stock | 34,126 | $3.30 | $112,615.80 |
DisclosureSEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · nonDerivative · entry 2 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,606 Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:14 UTC |
Grossman Adam SDirector · President and CEO
|
Exercise / conversionCommon Stock | 42,021 | $2.68 | $112,616.28 |
DisclosureSEC source: 0001193805-17-001300 · e616386_4-agrossman.xml · nonDerivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:13 UTC |
Grossman Jerrold BDirector
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 48,185 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · derivative · entry 5 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,185 shares Expires 2017-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested in equal monthly installments over the four (4) year period following July 16, 2007. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:13 UTC |
Grossman Jerrold BDirector
|
Tax withholdingCommon Stock | 39,132 | $3.30 | $129,135.60 |
DisclosureSEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,086 Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:13 UTC |
Grossman Jerrold BDirector
|
Exercise / conversionCommon Stock | 48,185 | $2.68 | $129,135.80 |
DisclosureSEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:01 UTC |
GOLDSTEIN DOV A MDDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001054 · e616261_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 7, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:04 UTC |
LENZ BRIANVP, CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 192,472 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001061 · e616268_4-lenz.xml · derivative · entry 1 LENZ BRIAN · CIK 0001283260 · VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,472 Underlying: Common Stock · 192,472 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:01 UTC |
Mond JamesEVP, CSO and CMO
|
GrantEmployee Stock Option (right to buy) · Derivative | 242,546 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001055 · e616262_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · EVP, CSO and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,546 Underlying: Common Stock · 242,546 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:03 UTC |
ELMS STEVEDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001058 · e616265_4-elms.xml · derivative · entry 1 ELMS STEVE · CIK 0001250195 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:02 UTC |
RICHMAN ERIC IDirector
|
GrantStock Option (right to buy) · Derivative | 78,144 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001056 · e616263_4-richman.xml · derivative · entry 1 RICHMAN ERIC I · CIK 0001313876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,144 Underlying: Common Stock · 78,144 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:04 UTC |
Guiheen Lawrence P.Director
|
GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001060 · e616267_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:03 UTC |
Grossman Adam SDirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 583,224 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001059 · e616266_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,224 Underlying: Common Stock · 583,224 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:02 UTC |
Grossman Jerrold BDirector
|
GrantStock Option (right to buy) · Derivative | 118,861 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001057 · e616264_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,861 Underlying: Common Stock · 118,861 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:00 UTC |
Fong BryantDirector
|
GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001053 · e616260_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:14 UTC |
GOLDSTEIN DOV A MDDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000280 · e615793_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:08 UTC |
LENZ BRIANChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000274 · e615800_4-lenz.xml · derivative · entry 1 LENZ BRIAN · CIK 0001283260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:15 UTC |
ELMS STEVEDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000281 · e615788_4-elms.xml · derivative · entry 1 ELMS STEVE · CIK 0001250195 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:14 UTC |
RICHMAN ERIC IDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000279 · e615794_4-richman.xml · derivative · entry 1 RICHMAN ERIC I · CIK 0001313876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:30 UTC |
Guiheen Lawrence P.Director
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000282 · e615795_4-guiheen.xml · derivative · entry 1 Guiheen Lawrence P. · CIK 0001554353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:13 UTC |
Fong BryantDirector · 10% owner
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000278 · e615796_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:12 UTC |
Grossman Jerrold BDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000277 · e615797_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:11 UTC |
Mond JamesCSO/CMO
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000276 · e615798_4-mond.xml · derivative · entry 1 Mond James · CIK 0001554537 · CSO/CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:10 UTC |
Grossman Adam SDirector · President & CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000275 · e615799_4-agrossman.xml · derivative · entry 1 Grossman Adam S · CIK 0001542517 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.